We’re excited to be partnering with @ProfluentBio, an innovative AI lab for biology that will apply its foundational AI models to generate novel enzyme therapies for BioMarin.

Profluent will design and optimize potential medicines using the largest protein sequence dataset in the world, composed of more than 115 billion unique sequences. Our scientists will screen these protein designs and evaluate the most promising candidates to advance to preclinical models, accelerating our early stage research and development in metabolic conditions.

Read more: http://ms.spr.ly/6013aYRXN